thebench.bio #1 Ecosystem for the Bio-Tech Industry

Funding Daily Summary

Funding Daily Summary: What Happened on November 14, 2026

Windward raises $225 million in IPO and Sanofi private placement

PhaSER received a renewed Gates Foundation grant, while Rezera postponed its planned offering.

  • Updated
  • Read from 4 articles, 4 publications
  • P

Today in brief

Windward Bio Group raised $225 million through an IPO and a separate investment from Sanofi.12 The money will fund two respiratory and immunology programs, with data expected in 2027 and pivotal asthma results expected in 2029.23

Windward raises $225 million for two antibody programs

Windward priced about 10.3 million IPO shares at $17 each, raising $175 million, and secured another $50 million from Sanofi in a private placement.23 The offering was priced at the midpoint of its proposed range, and Windward shares rose 68% in after-hours trading Friday.12

The proceeds will mainly support WIN378, an antibody targeting TSLP that is being tested for severe asthma and chronic obstructive pulmonary disease, and WIN027, which blocks TSLP and IL-13.23 Windward expects asthma and COPD data for WIN378 and early results for WIN027 in 2027.23 The company expects preliminary results from two pivotal asthma studies in the first half of 2029 and estimates its cash will last into that period.23

Also worth knowing

  • P

    PhaSER Biomedical received a two-year, $2.7 million Gates Foundation grant renewal to support neglected-disease drug research using its humanized mouse models.4

  • Rezera postponed its planned offering amid volatile market conditions.12

Also published